Back to News
Market Impact: 0.35
Galderma Reports Positive Topline Results For Restylane Volyme In Temple Hollowing Study
Source: Nasdaq
Healthcare & BiotechProduct Launches
Galderma reported positive topline results for Restylane Volyme in a study targeting moderate-to-severe temple hollowing. The study met its primary endpoint, supporting the product's efficacy profile and potentially expanding Galderma's aesthetics-market opportunity.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
GALD0.72
More News
- Snap tries to bring AR glasses to enterprise market, partnering with Nvidia, AWS and Salesforce
- Snap Shares More Details About $2,195 Specs AR Glasses, Plus Verizon Partnership
- Why is Snap stock climbing after-hours today?
- Snap launches $2,195 Specs augmented-reality glasses as AI push expands
- Snap tries to make the case again for its $2,200 smart glasses
- Premarket movers: Intel jumps on SK Hynix memory-chip talks, J.B. Hunt slides